[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-treatment-related\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-treatment-related":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,41,69,93,126,155,180,210,238,267,294],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100642172","physical-exercise-during-the-cancer-care-pathway-100642172",false,"NCT07652502","Physical Exercise During the Cancer Care Pathway","ECOLE","Inclusion Criteria:\n\n* Age ≥18 years\n* Oncological diagnosis\n* Ability to understand the language of the respective country of origin\n* Electronic informed consent\n\nExclusion Criteria:\n\n\\- Failure to accept the informed consent","ALL","18 Years",{"count":19,"type":20},370,"ESTIMATED","OBSERVATIONAL","Background: Physical exercise is proven safe and effective in improving quality of life and reducing treatment-related side effects in oncology. However, patient adherence to international guidelines remains suboptimal. Investigating the knowledge, attitudes, and practices (KAP) regarding physical activity is crucial to identifying unmet educational needs and barriers.\n\nObjective: This multicenter, cross-sectional observational study (ECOLE project) aims to assess KAP levels concerning exercise among cancer patients and explore the correlations between KAP scores and sociodemographic or clinical variables.\n\nMethods: Over a 6-month period, an anonymous online survey (Microsoft Forms) will be administered to adult cancer patients (≥18 years old) at any disease or treatment stage. A minimum sample size of 370 participants is targeted. Statistical analyses will include Descriptive Statistics, Exploratory and Confirmatory Factor Analyses to validate KAP scales, and Multivariable Logistic Regression to identify predictors of adherence (≥150 minutes\u002Fweek) and perceived barriers or facilitators.\n\nExpected Results: The study will provide a comprehensive overview of physical activity perceptions and behaviors in oncology. These insights will support the design of targeted educational interventions and structured exercise programs, contributing to the development of a novel \"Exercise Oncology Specialist\" within supportive care teams.",[24,25,26,27],"Cancer, Treatment-Related","Cancer","Oncology","Oncologic Disorders","NOT_YET_RECRUITING","2026-06-23",{"date":31,"type":32},"2026-06-26","ACTUAL",{"date":34,"type":20},"2026-06-15",{"date":36,"type":20},"2027-10-30",{"name":38,"class":39},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",2,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100490275","the-safety-and-efficacy-of-redsenol-1-plus-on-cancer-related-fatigue-in-adults-100490275","NCT05664009","The Safety and Efficacy of Redsenol-1 Plus on Cancer-related Fatigue in Adults","A Randomized, Triple-blind, Placebo Controlled, Parallel Clinical Trial to Investigate the Safety and Efficacy of Redsenol-1 Plus on Cancer-related Fatigue in Adults","Inclusion Criteria:\n\n1. Males and females ≥18 years of age\n2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or,\n\n   Females of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n3. Individuals previously diagnosed with cancer and have CRF defined as a score of ≥4 on the CRF Single-Item Scale (an 11-point scale where 0 is \"no fatigue\" and 10 is \"as bad as it can be\")\n4. CRF present for at least one month prior to screening\n5. Eastern Cooperative Oncology Group (ECOG) Performance Status Scale score ≤2\n6. Hemoglobin level of ≥110 g\u002FL for females and ≥129 g\u002FL for males at screening\n7. Agrees to maintain current lifestyle habits as much as possible throughout the study depending on ability to maintain the following: diet, medications, supplements, exercise, and sleep and avoid taking new supplements during the study period\n8. Provided voluntary, written, informed consent to participate in the study\n9. Otherwise healthy as determined by medical history and laboratory results as assessed by Qualified Investigator (QI) while taking into consideration the participant's cancer history\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Allergy, sensitivity, or intolerance to the investigational product's or placebo's active or inactive ingredients\n3. Individuals with any CNS malignancies (e.g., brain or spine) and\u002For estrogen-receptor positive breast cancer\n4. Individuals with other primary causes of fatigue, as assessed by the QI (e.g., diagnosed non-cancer related chronic pain, insomnia\u002Fsleep disorders, depression\u002Fpsychiatric disorders, unstable hypothyroidism, diabetes, gastrointestinal disease or symptoms that can affect nutritional balance)\n5. Individuals with unstable medical conditions as assessed by the QI\n6. Individuals with current untreated\u002Funcontrolled high blood pressure or tachycardia\u002Fheart rhythm disorders\n7. Individuals with \\>7.5% HbA1c with treatment for high blood sugar\u002Fdiabetes or individuals with ≥6.5% HbA1c without treatment\n8. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n9. History of or current diagnosis with kidney and\u002For liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n10. Major non-cancer surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n11. Current use of prescription\u002FOTC medications and\u002For supplements and food\u002Fdrinks which may affect the efficacy and\u002F or safety of the IP (see Sections 5.4.1 and 5.4.2)\n12. Alcohol or drug abuse within the last 12 months\n13. Frequent (daily) and chronic cannabis users. Occasional (e.g., once per month) cannabis users may be included at the discretion of the QI and if eligible, asked to stop cannabis use for study period\n14. Clinically significant abnormal laboratory results inclusive of thyroid stimulating hormone at screening as assessed by the QI\n15. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI\n16. Individuals who are unable to give informed consent\n17. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant",{"count":49,"type":20},72,"INTERVENTIONAL",[52],"NA","The primary objective of this study is to evaluate the safety and efficacy of Redsenol-1 Plus on cancer-related fatigue (CRF) in adults. The change in the severity of CRF from baseline at week 12 will be assessed by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) fatigue subscale, and compared between Redsenol-1 Plus and placebo groups. Additionally, the safety and tolerability of Redsenol-1 Plus, as compared to placebo, will be measured by the occurrence of and\u002For changes in treatment-emergent adverse events (AEs).",[55,24],"Fatigue",[57,58,59],"Safety and efficacy","Cancer-related fatigue","Ginseng",{"date":31,"type":32},{"date":62,"type":20},"2026-08",{"date":64,"type":20},"2026-12",{"name":66,"class":67},"Canada Royal Enoch Phytomedicine Co., Ltd.","INDUSTRY",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":50,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":68},"100477067","unravelling-the-impact-of-radiofrecuency-in-liver-surgery-the-key-to-decrease-local-recurrence-100477067","NCT05492136","Unravelling the Impact of Radiofrecuency in Liver Surgery: the Key to Decrease Local Recurrence?","Unravelling the Impact of Radiofrecuency in Liver Surgery: the Key to Decrease Local Recurrence? (Study LIVERaTION)","LIVERaTION","Inclusion criteria:\n\n1. Written informed consent granted prior to the initiation of the surgical procedure, given with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.\n2. 18 year of age or older.\n3. WHO performance scale 0-2\n4. Consecutive patients (both sexes equally distributed) suffering from CRLM confirmed either by abdominal CT, abdominal MRI or\u002Fand by histologic-cytological evaluation or patients suffering from HCC.\n5. Any previous chemotherapy regime is permitted.\n6. ASA score 1 to 3.\n\nExclusion criteria:\n\n1. Previous or concurrent cancer that is distinct from one primary tumor of which the Liver metastasis comes from EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis \\& T1).\n2. Any cancer curatively treated \\> 3 years prior to enrollment is permitted.\n3. ASA 4.\n4. Non-resectable extrahepatic metastases.\n5. Liver metastasis from other origin apart from colorectal.\n6. Bening primary tumor of the liver.\n7. Pregnant woman.\n8. Participation in another clinical trial.",{"count":78,"type":20},720,[52],"Radiofrequency devices have been increasingly employed in liver surgery in order to achieve proper hemostasis and this use has become more evident with the implementation of minimal invasive surgery. Due to its well-known efficacy for tumor ablation (i.e. hepatocarcinoma) it use has been extended in some cases to ablate the liver surface after resection in questionable resection. Till date, despite the majority of surgeons apply an additional coagulation in doubtful margins, there is not an evidence that this maneuver really decreases the local recurrence or increases the overall survival. On the contrary, some studies have suggested that non-anatomical resections in order to spare liver parenchyma could lead to major zones of liver ischemia in the remnant liver and thus favoring recurrence. However, major liver ischemia (defined as grade 2 o more) is unlikely to be provoked by 1 cm-depth additional coagulation of the margin.\n\nThe investigators previously published in a retrospective study the concept of additional margin coagulation within liver resections and narrow margins and demonstrated that the study group had significantly less local recurrence compared to the controls. Therefore, in the present study the aim is to continue this evaluation through a multicenter randomized clinical trial.",[82,24],"Liver Cancer","RECRUITING","2025-09-01",{"date":86,"type":32},"2025-09-03",{"date":88,"type":32},"2023-11-01",{"date":90,"type":20},"2028-06-30",{"name":92,"class":39},"Hospital del Mar",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":101,"targetDuration":103,"studyType":21,"phases":4,"briefSummary":104,"conditions":105,"keywords":110,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100603787","the-impact-of-emotional-stress-on-immunotherapy-outcomes-in-liver-cancer-patients-a-multi-cohort-study-100603787","NCT07141056","The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study","Impact of Emotional Stress on Immune Checkpoint Inhibitor Treatment Outcomes in Hepatocellular Carcinoma: A Multicohort Clinical Study","SOLACE","Cohort 1 (SOLACE-1):\n\nInclusion Criteria:\n\n* Age ≥ 18 years\n* Able to complete psychological questionnaires\n* Child-Pugh liver function class A\n* ECOG performance status ≤ 1\n* Signed informed consent\n* Expected survival \\> 3 months\n* Diagnosed with unresectable HCC by pathology or imaging\n* BCLC stage B or C\n* Has at least one measurable lesion (mRECIST)\n* About to receive first-line ICI treatment\n\nExclusion Criteria:\n\n* Currently taking antidepressant or anti-anxiety medications\n* Previous diagnosis of psychiatric disorders\n* Concurrent malignancy\n* Unable to complete psychological assessments\n* Previous systemic anti-tumor therapy\n* Symptomatic brain metastases\n* Child-Pugh score \\> 7\n\nCohort 2 (SOLACE-2):\n\nInclusion Criteria:\n\n* Age ≥ 18 years\n* Able to complete psychological questionnaires\n* Child-Pugh liver function class A\n* ECOG performance status ≤ 1\n* Signed informed consent\n* Expected survival \\> 3 months\n* Pathologically confirmed HCC after curative surgery\n* Pathological stage II or III (AJCC 8th edition)\n* Will start adjuvant ICI therapy within 4-6 weeks after surgery\n* Expected survival \\> 12 months\n\nExclusion Criteria:\n\n* Currently taking antidepressant or anti-anxiety medications\n* Previous diagnosis of psychiatric disorders\n* Concurrent malignancy\n* Unable to complete psychological assessments\n* Residual lesions after surgery\n* Child-Pugh score B or C\n\nCohort 3 (SOLACE-3):\n\nInclusion Criteria:\n\n* Age ≥ 18 years\n* Able to complete psychological questionnaires\n* Child-Pugh liver function class A\n* ECOG performance status ≤ 1\n* Signed informed consent\n* Expected survival \\> 3 months\n* Diagnosed with resectable HCC by pathology or imaging\n* Has at least one measurable lesion (RECIST 1.1)\n* About to receive neoadjuvant ICI treatment\n* Expected survival \\> 12 months\n\nExclusion Criteria:\n\n* Currently taking antidepressant or anti-anxiety medications\n* Previous diagnosis of psychiatric disorders\n* Severe cardiac, pulmonary, or renal dysfunction\n* Concurrent malignancy\n* Unable to complete psychological assessments\n* Previous systemic anti-tumor therapy\n* Symptomatic brain metastases\n* Child-Pugh score B or C",{"count":102,"type":20},700,"36 Months","The goal of this observational study is to learn if emotional distress affects how well liver cancer treatment works in people receiving immunotherapy. Emotional distress means feeling anxious or depressed. The study aims to answer whether having emotional distress before treatment or changes in emotional distress during treatment affect how well immunotherapy works to treat liver cancer. Researchers will compare participants with and without emotional distress to examine differences in how long the cancer stays under control, treatment response, and overall survival time. Study participants will complete mood and quality of life questionnaires, meet with mental health specialists for emotional assessments, undergo regular blood tests to measure stress hormones, have routine medical check-ups and scans to monitor their cancer status, and be followed for up to 3 years. The study includes three groups of people with liver cancer: those starting immunotherapy for cancer that cannot be removed by surgery, those receiving immunotherapy after surgery, and those receiving immunotherapy before surgery. To be eligible for participation, individuals must be 18 years or older, diagnosed with liver cancer, about to start immunotherapy treatment, and able to complete mood questionnaires.",[106,107,108,24,109],"HCC - Hepatocellular Carcinoma","Psychological Distress","Immune Checkpoint Inhibitors (ICIs)","Unresectable Hepatocellular Carcinoma",[111,112,113,114,115],"Observational Study","Hepatocellular Carcinoma (HCC)","Emotional Distress","Immune Checkpoint Inhibitors","Cancer Immunotherapy","2025-08-18",{"date":118,"type":32},"2025-08-26",{"date":120,"type":32},"2025-01-01",{"date":122,"type":20},"2027-12-31",{"name":124,"class":39},"Guilin Medical University, China",5,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":136,"studyType":21,"phases":4,"briefSummary":137,"conditions":138,"keywords":141,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":68},"100591050","the-associations-of-sleep-disturbance-with-therapy-efficacy-and-prognosis-of-lung-cancer-100591050","NCT06975384","The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer","The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer, Including Non-small-cell Lung Cancer and Small-cell Lung Cancer With Early and Advanced Staging","Nezha","Cohort 1:\n\nInclusion Criteria:\n\n1. Age ≥ 18 years old;\n2. Histologically confirmed diagnosis of NSCLC;\n3. Unresectable locally advanced, metastatic, or recurrent stage ⅢB-Ⅳ based on AJCC TNM staging 8th edition;\n4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1;\n5. Treatment naïve;\n6. Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1);\n7. Receiving PD-1\u002FPD-L1 inhibitors monotherapy or combination with chemotherapy;\n8. Informed consent to participate in the study;\n\nExclusion Criteria:\n\n1. Epidermal growth factor receptor (EGFR)-sensitizing mutation and\u002For anaplastic lymphoma kinase (ALK) fusion and\u002For ROS proto-oncogene 1 (ROS1) fusion-positive;\n2. Presence of other malignant tumors or malignant diseases within 3 years;\n3. Concurrent acute or chronic psychiatric disorders;\n4. Patients receiving sleep medication;\n5. Prior participation in other clinical drug trials;\n6. Symptomatic brain metastasis;\n7. Inability to complete scale assessments.\n\nCohort 2:\n\nInclusion Criteria:\n\n1. Age ≥ 18 years old;\n2. Histologically confirmed diagnosis of SCLC；\n3. Unresectable locally advanced, metastatic, or recurrent stage Ⅲ-Ⅳ based on AJCC TNM staging 8th edition;\n4. ECOG PS of 0-1;\n5. Treatment naïve;\n6. Presence of at least one measurable lesion according to the RECIST v1.1 ;\n7. Receiving PD-1\u002FPD-L1 inhibitors monotherapy or combination with chemotherapy;\n8. Informed consent to participate in the study;\n\nExclusion Criteria:\n\n1. Presence of other malignant tumors or malignant diseases within 3 years;\n2. Concurrent acute or chronic psychiatric disorders;\n3. Patients receiving sleep medication;\n4. Prior participation in other clinical drug trials;\n5. Symptomatic brain metastasis;\n6. Inability to complete scale assessments.\n\nCohort 3:\n\nInclusion Criteria:\n\n1. Age ≥18 years old;\n2. Pathologically diagnosed as NSCLC;\n3. Resectable clinical stage IB-IIIB based on AJCC TNM staging 8th edition;\n4. At least one measurable lesion can be evaluated according to the RECIST v1.1;\n5. Treatment naïve;\n6. Receiving PD-1\u002FPD-L1 inhibitors monotherapy or combination with chemotherapy as neoadjuvant therapy;\n7. Cardiopulmonary function can withstand surgery;\n8. Informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. EGFR-sensitizing mutation and\u002For ALK fusion and\u002For ROS1 fusion-positive;\n2. Presence of other malignant tumors or malignant diseases within 3 years;\n3. Concurrent acute or chronic psychiatric disorders;\n4. Patients receiving sleep medication;\n5. Prior participation in other clinical drug trials;\n6. Symptomatic brain metastasis;\n7. Inability to complete scale assessments.\n\nCohort 4:\n\nInclusion Criteria:\n\n1. Age ≥ 18 years old;\n2. Pathologically diagnosed as NSCLC;\n3. Pathologically stage confirmed as early stage of IA-IIIA;\n4. Available for tumor tissue samples;\n5. Treatment naïve;\n6. Receiving radical surgery;\n7. Informed consent to participate in the study;\n\nExclusion Criteria:\n\n1. Presence of other malignant tumors or malignant diseases within 3 years;\n2. Concurrent acute or chronic psychiatric disorders;\n3. Patients receiving sleep medication;\n4. Prior participation in other clinical drug trials;\n5. Inability to complete scale assessments.\n\nCohort 5:\n\nInclusion Criteria:\n\n1. Age ≥ 18 years old;\n2. Histologically confirmed diagnosis of NSCLC;\n3. Unresectable locally advanced, metastatic, or recurrent stage ⅢB-Ⅳ based on AJCC TNM staging 8th edition;\n4. ECOG PS of 0-1;\n5. Treatment naive;\n6. Presence of at least one measurable lesion according to the RECIST v1.1;\n7. Receiving targeted therapy or combination with chemotherapy;\n8. Informed consent to participate in the study;\n9. Driver gene-positive.\n\nExclusion Criteria:\n\n1. Presence of other malignant tumors or malignant diseases within 3 years;\n2. Concurrent acute or chronic psychiatric disorders;\n3. Patients receiving sleep medication;\n4. Prior participation in other clinical drug trials;\n5. Symptomatic brain metastasis;\n6. Inability to complete scale assessments.",{"count":135,"type":20},1270,"5 Years","This is the prospective, observational cohort study (Nezha) to explore the associations of sleep disturbance with progression, efficacy of immune checkpoint inhibitors (ICIs) and prognosis of Lung Cancer. The participants including the patients diagnosed with advanced non-small-cell lung cancer (NSCLC) who received either first-line therapy (ICIs or targeted agents) or neoadjuvant therapy with ICIs; patients diagnosed with advanced small-cell lung cancer (SCLC) receiving the first-line therapy ICIs; patients diagnosed with early non-small-cell lung cancer (NSCLC) receiving surgery.",[139,140,114,24],"Lung Cancer","Sleep Disturbance",[139,114,140,142,143,144,145],"Circadian Rhythm","Cancer Progression","Prognosis","Biomarker","2025-05-09",{"date":148,"type":32},"2025-05-16",{"date":150,"type":32},"2024-11-01",{"date":152,"type":20},"2030-12-31",{"name":154,"class":39},"Second Xiangya Hospital of Central South University",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":162,"targetDuration":136,"studyType":21,"phases":4,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":68},"100475980","the-associations-of-psychological-stress-with-therapy-efficacy-and-prognosis-of-lung-cancer-stress-lung-100475980","NCT05477979","The Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer (STRESS-LUNG)","Cohort Studies of Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer, Including Non-small-cell Lung Cancer and Small-cell Lung Cancer With Early and Advanced Staging (STRESS-LUNG)","Cohort 1 (STRESS-LUNG-1):\n\nInclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Histologically confirmed diagnosis of NSCLC;\n3. Unresectable locally advanced, metastatic, or recurrent stage ⅢB-Ⅳ based on AJCC TNM staging 8th edition;\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;\n5. Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy );\n6. Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1) ;\n7. Receiving PD-1\u002FPD-L1 inhibitors monotherapy or combination with chemotherapy;\n8. Informed and agreed to participate in the study;\n\nExclusion Criteria:\n\n1. Epidermal growth factor receptor (EGFR)-sensitizing mutation and\u002For anaplastic lymphoma kinase (ALK) gene and\u002For ROS proto-oncogene 1 (ROS1) fusion-positive;\n2. Combined with other malignant tumors in the past 3 years;\n3. Concurrent acute or chronic psychiatric disorders;\n4. Current receiving anti-depressive or anti-anxiety therapy;\n5. Previous treatment with other clinical drug trials;\n6. Patients with symptomatic brain metastasis;\n7. Can't cooperate with psychological scale assessment;\n\nCohort 2 (STRESS-LUNG-2):\n\n1. Age ≥ 18 years；\n2. Pathologically diagnosed as small cell lung cancer；\n3. Unresectable locally advanced, metastatic, or recurrent stage Ⅲ-Ⅳ based on AJCC TNM staging 8th edition;\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;\n5. Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy );\n6. Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1) ;\n7. Receiving PD-1\u002FPD-L1 inhibitors monotherapy or combination with chemotherapy;\n8. Informed and agreed to participate in the study;\n\nExclusion Criteria:\n\n1. Combined with other malignant tumors in the past 3 years;\n2. Concurrent acute or chronic psychiatric disorders;\n3. Current receiving anti-depressive or anti-anxiety therapy;\n4. Previous treatment with other clinical drug trials;\n5. Patients with symptomatic brain metastasis;\n6. Can't cooperate with psychological scale assessment;\n\nCohort 3 (STRESS-LUNG-3):\n\n1. Age ≥18 years ；\n2. Pathologically diagnosed as non-small cell lung cancer;\n3. Resectable clinical stage IB-IIIB based on AJCC TNM staging 8th edition;\n4. At least one measurable lesion can be evaluated according to the RECIST 1.1 standard；\n5. Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy );\n6. Receiving PD-1\u002FPD-L1 inhibitors combined with chemotherapy as neoadjuvant therapy.\n\n6\\. Cardiopulmonary function can withstand surgery; 7. Informed and agreed to participate in the study;\n\nExclusion Criteria:\n\n1. Epidermal growth factor receptor (EGFR)-sensitizing mutation and\u002For anaplastic lymphoma kinase (ALK) gene and\u002For ROS proto-oncogene 1 (ROS1) fusion-positive;\n2. Combined with other malignant tumors in the past 3 years;\n3. Concurrent acute or chronic psychiatric disorders;\n4. Current receiving anti-depressive or anti-anxiety therapy;\n5. Previous treatment with other clinical drug trials;\n6. Can't cooperate with psychological scale assessment;\n\nCohort 4 (STRESS-LUNG-4):\n\n1. Age ≥18 years;\n2. Pathologically diagnosed as non-small-cell lung cancer；\n3. Pathologically stage conformed as early stage of IA-IIIA\n4. Available for tumor tissue samples；\n5. Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy );\n6. Receiving radical surgery;\n7. Informed and agreed to participate in the study;\n\nExclusion Criteria:\n\n1. Combined with other malignant tumors in the past 3 years;\n2. Concurrent acute or chronic psychiatric disorders;\n3. Current receiving anti-depressive or anti-anxiety therapy;\n4. Previous treatment with other clinical drug trials;\n5. Can't cooperate with psychological scale assessment;",{"count":163,"type":20},750,"This is the prospective, observational cohort study (STRESS-LUNG) to explore the associations of psychological stress with progression, efficacy of immune checkpoint inhibitors (ICIs) and prognosis of Lung Cancer. The participants including the patients diagnosed with advanced non-small-cell lung cancer (NSCLC) who received the first-line therapy or neoadjuvant therapy of ICIs; patients diagnosed with advanced small-cell lung cancer (SCLC) receiving the first-line therapy ICIs; patients diagnosed with early small-cell lung cancer (SCLC) receiving surgery.",[139,166,114,24],"Psychological Stress",[168,169,170,171,144,145],"Lung cancer","Immune checkpoint inhibitors","Psychological stress","Cancer progression","2025-02-21",{"date":174,"type":32},"2025-02-25",{"date":176,"type":32},"2020-06-01",{"date":178,"type":20},"2028-12-31",{"name":154,"class":39},{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":50,"phases":190,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":209},"100536774","postoperative-complications-in-cancer-patients-monitored-with-intelligent-continuous-monitoring-system-100536774","NCT06269198","Postoperative Complications in Cancer Patients Monitored With Intelligent Continuous Monitoring System","Postoperative Complications in Cancer Patients Monitored With Intelligent Continuous Monitoring System Versus Standard of Care - a Randomized Clinical Trial","WARD-SX-RCT-II","Inclusion Criteria:\n\n* Admission for elective major abdominal (gastrointestinal, gynecological, or urological) surgery with the primary aim of radical surgery\u002Fremoving suspected cancer tissue.\n* At least two expected postoperative admission days\n* Laparotomy or laparoscopy procedure estimated to last more than 2 hours.\n* Co-enrolment of patients in other studies is acceptable but in studies involving interventions which potentially will affect the continuous monitoring of vital signs and\u002For the primary or secondary outcomes, an assessment of whether these patients can be co-enrolled in the WARD-RCT should be conferred with the WARD RCT steering committee.\n\nExclusion Criteria:\n\n* Patient expected not to cooperate with study procedures\n* Allergy to study materials (silicone, plaster)\n* Impaired cognitive function (in uncertain cases assessed by a Mini Mental State Examination score \\\u003C 24). (Protocol Appendix E)\n* Patients with a pacemaker or Implantable Cardioverter Defibrillator (ICD) device\n* Inability to give informed consent\n* Patients with planned hyperthermic intraperitoneal chemotherapy (HIPEC) procedure or two-stage resections (two-stage hepatectomy, two-stage resection of malignant colorectal obstructions, etc.)",{"count":189,"type":20},504,[52],"The primary objective of this study is to determine the effect on complication severity of using a clinical monitoring system with automatic vital sign alerts in addition to routine monitoring versus routine monitoring alone in high-risk postoperative cancer patients within 30 days after surgery.\n\nOther objectives include documentation of the severity of complications within seven days of surgery, frequency of serious adverse events, mortality, length of stay and delay of planned chemotherapy.",[193,24],"Postoperative Complications",[195,196,197,198,199],"vital signs","continuous monitoring","wireless monitoring","postoperative physiology","postoperative complications","2025-01-13",{"date":202,"type":32},"2025-01-15",{"date":204,"type":32},"2023-10-31",{"date":206,"type":20},"2027-04-01",{"name":208,"class":39},"Rigshospitalet, Denmark",3,{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":216,"sex":16,"minAge":17,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":68},"100566307","development-and-demonstration-of-intelligent-assessment-based-on-multi-modal-information-fusion-for-tumor-risk-and-diagnosis-and-treatment-100566307","NCT06653478","Development and Demonstration of Intelligent Assessment Based on Multi-modal Information Fusion for Tumor Risk and Diagnosis and Treatment","Inclusion Criteria:\n\n1. Participants with the suspected of lung cancer\u002Fnode, or stomach cancer\u002Flesion, or colorectal cancer\u002Fleision\n2. Participants that have signed informed consent.\n3. Participants with detailed electronic medical records, image records, pathological records, multi-omics information, and other important clinical diagnostic information.\n4. Healthy participants with no clinical diagnosis of lung cancer\u002Fnode, or stomach cancer\u002Flesion, or colorectal cancer\u002Fleision.\n\nExclusion Criteria:\n\n1. Participants with primary clinical and pathological data missing.\n2. Participants lost to follow-up.\n3. Participants with too poor medical image quality to perform segment and mark ROI accurately",true,"75 Years",{"count":219,"type":20},3000,"To improve the accuracy of risk prediction, screening and treatment outcome of cancer, we aim to establish a medical database that includes standardized and structured clinical diagnosis and treatment information, image features, pathological features, and multi-omics information and to develop a multi-modal data fusion-based technology system using artificial intelligence technology based on database.",[222,223,139,224,225,226,227,228,24],"Artificial Intelligence","Deep Learning","Lung; Node","Stomach Cancer","Colon Cancer","Cancer Risk","Cancer Screening","2024-10-20",{"date":231,"type":32},"2024-10-22",{"date":233,"type":32},"2022-06-01",{"date":235,"type":20},"2026-10-01",{"name":237,"class":39},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":245,"minAge":17,"maxAge":246,"enrollmentInfo":247,"targetDuration":249,"studyType":21,"phases":4,"briefSummary":250,"conditions":251,"keywords":254,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":265,"locationsCount":68},"100561231","testicular-function-and-semen-quality-in-male-childhood-and-adolescent-cancer-survivors-100561231","NCT06587477","Testicular Function and Semen Quality in Male Childhood and Adolescent Cancer Survivors","Effect of Cancer Treatment on Testicular Function and Semen Quality in Male Childhood and Adolescent Cancer Survivors","Inclusion Criteria:\n\n* Men who have received chemotherapy and\u002F or radiotherapy for cancer diagnosed when they were \\\u003C 18 years old.\n* \\> 18 years old to 50 years old\n* Cancer in remission for at least 2 years\n\nExclusion Criteria:\n\n* Unable to ejaculate by masturbation to provide semen samples\n* Cryptorchidism, testicular cancer, history of vasectomy\n* On testosterone replacement therapy\n* Refusal to join the study","MALE","50 Years",{"count":248,"type":20},200,"3 Weeks","Cancer treatment can affect the testicular function, including sperm and hormonal functions. The aim of this study is to assess the testicular function and semen quality in young men who recover from childhood and adolescent cancer in Hong Kong. This can provide more information for pre-treatment counselling as well as improve post treatment survivorship care. The testicular function will be compared to aged-matched controls from men attending the Family Planning Association for premarital check-up.",[24,252,253],"Late Effect","Semen Analysis",[255,256,257,258],"cancer treatment","testicular function","semen quality","cancer survivors","2024-09-06",{"date":261,"type":32},"2024-09-19",{"date":263,"type":32},"2023-01-16",{"date":90,"type":20},{"name":266,"class":39},"The University of Hong Kong",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":216,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":50,"phases":276,"briefSummary":277,"conditions":278,"keywords":282,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":290,"leadSponsor":292,"locationsCount":4},"100556301","culinary-medicine-for-cancer-caregivers-100556301","NCT06523322","Culinary Medicine for Cancer Caregivers","Culinary Medicine for Caregivers: Improving Pediatric Cancer Patient and Caregiver Outcomes Through Nutrition and Culinary Support","\\*Please note the above age limit and 'accepts health volunteers' specifications are related to the caregiver as the participant. Additional age limit criteria for patient is listed below. All caregivers will be providing care for a child undergoing current cancer treatment.\n\nInclusion Criteria, Patient:\n\n* Receiving active cancer treatment for a liquid or solid cancer diagnosis\n* At least 4-17 years of age\n* English-speaking\n* Taking \\>50% intake orally\n* Approved to participate by both their oncologist and registered dietitian nutritionist\n\nExclusion Criteria, Patient:\n\n* Undergoing bone marrow transplantation\n* Receiving active cancer treatment for a brain tumor\n\nInclusion Criteria, Caregiver:\n\n* Caregiver (parent or legal guardian) of a child who meets the inclusion and exclusion criteria for patients, above\n* Can read and speak English\n* Has access to a computer (i.e., tablet, laptop, desktop computer) and internet\n* Is at least 18 years of age\n* Has the ability to provide informed consent",{"count":275,"type":20},20,[52],"Pediatric cancer and the therapies used in treatment can affect nutritional status, which can impact treatment tolerance, survival, and overall well-being. Poorly managed side effects can lead to long-term poor dietary habits. Caregivers who endure the psychosocial toll of these effects, also face risks to their own well-being. Prioritizing interventions that enhance caregivers' ability to provide quality care and improve long-term health is crucial. The primary aim of this study is to determine the feasibility and acceptability of an 8-week culinary medicine intervention with caregiver coaching for caregivers of children undergoing cancer treatment. The secondary aim is to estimate the effect of the intervention on caregiving preparedness, caregiver self-confidence for managing patient treatment side effects, eating-related distress, and dietary intake. In-depth interviews will explore participant experiences and perspectives on the feasibility and acceptability of the culinary nutrition program, and to inform interpretation of findings and future program refinement.",[279,280,24,281],"Pediatric Cancer","Caregiver Burden","Nutrition Aspect of Cancer",[283,284,285],"Culinary medicine","Nutrition","Cancer caregiver","2024-07-25",{"date":288,"type":32},"2024-07-26",{"date":286,"type":20},{"date":291,"type":20},"2025-01-30",{"name":293,"class":39},"Drexel University",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":216,"sex":16,"minAge":17,"maxAge":217,"enrollmentInfo":300,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":220,"conditions":301,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":306,"leadSponsor":308,"locationsCount":68},"100471996","artificial-intelligence-system-for-assessment-of-tumor-risk-and-diagnosis-and-treatment-100471996","NCT05426135","Artificial Intelligence System for Assessment of Tumor Risk and Diagnosis and Treatment","Development of an Artificial Intelligence System for Assessment of Tumor Risk and Diagnosis and Treatment Based on Multimodal Data Fusion Using Deep Learning Technology",{"count":219,"type":20},[222,223,139,224,225,226,227,228,24],"2022-06-17",{"date":304,"type":32},"2022-06-21",{"date":233,"type":32},{"date":307,"type":20},"2026-10",{"name":237,"class":39}]